2018 News Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
02/21/18Anika Reports Fourth Quarter and Full Year 2017 Financial Results
MONOVISC Global Revenue Increased 21% Year-over-Year for Fourth Quarter of 2017; Total Revenue Increased 10% for Full Year of 2017 BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 21, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today reported financial results for the fourth quarter and full year e... 
Printer Friendly Version
02/07/18Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21
BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 7, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter 2017 financial results after the close of the market on Wednesday, February 21, 2017 and to hold a conference call the next day, Thursday, February 22, 2018, at 9:00 a.m. ET to discuss its financial results, business highlights, and outlook. The conference call can be accessed by dialing... 
Printer Friendly Version
02/01/18Anika Therapeutics Announces Strategic Collaboration with the Institute of Integrative Biology at the University of Liverpool to Develop an Innovative Therapy for Osteoarthritis
BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced an agreement with the Institute of Integrative Biology at the University of Liverpool to collaborate on research to develop an injectable mesenchymal stem cell (MSC) therapy for the treatment of oste... 
Printer Friendly Version
01/24/18Anika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid Arthritis
BEDFORD, Mass.--(BUSINESS WIRE)--Jan. 24, 2018-- A new agreement to extend a two-year-long strategic collaboration that yielded a promising new modality for the treatment of rheumatoid arthritis (RA) was today announced by Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, and the Institute for Applied Life Sciences at ... 
Printer Friendly Version